“Orforglipron and retatrutide from Eli Lilly exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior ...

Viking Therapeutics VKTX is one of the few companies with a late-stage obesity candidate in its pipeline. The company is ...

The discovery of GLP-1 and its role in regulating blood glucose was a major scientific breakthrough in diabetes research, yet turning this peptide hormone into an effective medication was no easy task ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide and liraglutide mimic endogenous incretin signals to stimulate glucose-dependent insulin release, thereby suppressing glucagon, ...

Researchers are exploring drugs like Ozempic, Mounjaro, and Wegovy to treat or prevent a range of conditions, including ...

Adolescents with overweight or obesity and asthma taking a GLP-1 agent had less risk of asthma exacerbations compared with ...

Please provide your email address to receive an email when new articles are posted on . GLP-1 receptor agonists and fenofibrate medications significantly reduced the risk for developing diabetic ...

BOGOTÁ, Colombia — Most dermatologists and rheumatologists agree that GLP-1 receptor agonists (GLP-1 RAs), such as liraglutide, semaglutide, and tirzepatide, powerful antidiabetes and weight-loss ...

As use of GLP-1 receptor agonists (RAs) continues to rise exponentially, awareness of its most common side effects, such as nausea and vomiting, is growing. But the drugs come with some lesser-known ...

Researchers have been examining other potential health benefits from GLP-1 agonist medications outside of type 2 diabetes management and weight loss. Recent studies have found that GLP-1 medications ...